.svg){kind=small}
DIA 3rd Cardiac Safety Workshop Explores the Future of the TQT Study And Issues Surrounding the Conduct and Analysis of TQT Studies in Japan
9
May 2012
Cardiovascular Safety and State-of-the-art Development Issues 2012: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity
19
March 2012
QT Assessment in Early Clinical Development Can the Predictive Value be Enhanced to be Similar to That of a TQT study?
15
January 2012
Further data to be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)
29
November 2011
Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup
8
November 2011
.avif)
Latest news
Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director
July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read moreUpcoming Event
ESC Congress 2026
28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event
